---
title: Improve daily functioning through teams
nct_id: NCT05433441
phase: NA
status: RECRUITING
sponsor: University Hospital, Bordeaux
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT05433441"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05433441"
last_fetched: "2026-05-10T14:08:43.516Z"
source: "Parkinson's Pathways (curated)"
---
# Improve daily functioning through teams

**Goal (in five words):** Improve daily functioning through teams

**Official Title:** Evaluation of the Effectiveness of the Parkinson's Specialized Teams Intervention on the Quality of Life of Parkinson's Patients in the Territory of the Nouvelle-Aquitaine and Hauts-de-France: ES-Park Pilot Study.

**Trial ID:** [NCT05433441](https://clinicaltrials.gov/study/NCT05433441)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** University Hospital, Bordeaux
- **Target Enrollment:** 250 participants
- **Start Date:** 2022-12-06
- **Completion Date:** 2025-12-06
- **Conditions:** Parkinson Disease
- **Interventions:** ESPark Intervention
- **Intervention Types:** PROCEDURE

## Summary For Families

The trial is testing whether specialized, multidisciplinary Parkinson's teams can improve quality of life for people with more advanced Parkinson's in the Nouvelle-Aquitaine and Hauts-de-France regions. The teams deliver coordinated, individualized care such as medication review, tailored physical and occupational therapy plans, home-based support and caregiver education, aiming to reduce disability, falls and daily burden rather than testing a drug. They are enrolling adults with idiopathic Parkinson's who are Hoehn and Yahr stage 3 or higher, have no major cognitive impairment (MOCA ≥21), live at home and have a willing nonprofessional caregiver. Both patient and caregiver must consent and be able to complete follow-up interviews, while people with dementia, imminent institutionalization, severe unstable illness or participation in other non-drug management trials are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

For the patient:

* Patient with a diagnosis of idiopathic Parkinson's disease
* Patient over 18 years ;
* Patient with a Hoehn and Yahr Stage greater than or equal to 3;
* Patient without major cognitive impairment defined by a MOCA score ≥21
* Patient living at home ;
* Patient with an identified non-professional primary caregiver;
* Person affiliated with or benefiting from a social security plan;
* Free, informed and and express consent (confirmed in writing) (no later than the day of inclusion and before any examination required by the research).

For the caregiver:

* Male or female over 18 years
* Able to respond to research interviews/questionnaires
* Free, informed and express consent (confirmed in writing) (no later than the day of inclusion and before any examination required by the research).

Exclusion Criteria:

For the patient:

* Patient with medically indicated dementia impairing comprehension and adherence, and/or with severe confusion or psycho-hallucinatory state;
* Institutionalized or foster care patients;
* Patients with a known severe and unstable general pathology that does not allow for patient follow-up;
* Patients already included in another non-drug management trial;
* Patients whose institutionalization is envisaged in the short term (within 6 months) or for whom a change of residence is envisaged in the short term and would not allow for follow-up assessments;
* Patients under guardianship or unable to express consent
* Primary caregiver not wishing to participate in the study or unable to be available for the planned study follow-up;
* Presence of a primary caregiver with a known severe and unstable disease that does not allow for the conduct of the study;
* Presence of a primary caregiver with a known cognitive or psychiatric disorder (chronic progressive psychosis) that does not allow for the proper conduct of the study.
* Pregnant or breastfeeding woman.

For the caregiver:

* Unable to follow the research interviews or questionnaires.
* Primary caregiver not wishing to participate in the study or unable to be available for the planned study follow-up;
* Primary caregiver with a known severe and unstable illness that does not allow for the proper conduct of the study;
* Primary caregiver with known cognitive or psychiatric disorders (chronic progressive psychosis) that do not allow the study to be conducted properly.
```

## Locations (4)

- Hopital Pellegrin, Bordeaux, France _(44.8412, -0.5805)_
  - Alexandra FOUBERT-SAMIER, Dr — (CONTACT) — alexandra.samier-foubert@u-bordeaux.fr
- CHU de Lille, Lille, France _(50.6339, 3.0551)_
  - Nicolas CARRIERE, Dr — (CONTACT) — 0320446752 — nicolas.carriere@chu-lille.fr
- CHU de Limoges, Limoges, France _(45.8336, 1.2476)_
  - Jean-Luc HOUETO, Pr — (CONTACT) — jean-luc.houeto@chu-limoges.fr
- CHU Poitiers, Poitiers, France _(46.5826, 0.3435)_
  - Isabelle BENATRU, Dr — (CONTACT) — isabelle.benatru@chu-poitiers.fr

## Central Contacts

- Alexandra FOUBERT-SAMIER, Dr — (CONTACT) — 05 57 82 12 53 — alexandra.samier-foubert@u-bordeaux.fr
- Sandrine DUPOUY — (CONTACT) — 05 57 82 14 62 — sandrine.dupouy@chu-bordeaux.fr

---

*Canonical: https://parkinsonspathways.com/trial/NCT05433441*  
*HTML version: https://parkinsonspathways.com/trial/NCT05433441*  
*Source data: https://clinicaltrials.gov/study/NCT05433441*